The HCPLive Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.
March 18th 2024
In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.
FAQs in Peanut Allergy: Exploring Unanswered Questions Following Allergy Meeting Updates
View More
Community Practice Connections™: Preparing for an Expanded Armamentarium for Food Allergy
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Tolly Epstein, MD, MS: Post-Injection Monitoring and Epinephrine for Patients on Immunotherapy
February 25th 2022Dr. Epstein provides updates on a joint study between members of AAAAI and the American College of Allergy on the relationship between epinephrine and post-immunotherapy injection waiting periods.
Dupilumab Reduces Blood Levels, Allergen-Specific IgE in Atopic Dermatitis Patients
November 5th 2021Data from the LIBERTY AD ADOL trial showed that adolescent patients with moderate-to-severe atopic dermatitis treated with the biologic reported decreases in total and allergen-specific IgE levels for cat dander, peanuts, and more.
Rebecca Rosenberger, MMSc, PA-C: Educating Patients on Allergy Symptoms
September 7th 2021In an interview with HCPLive, Rosenberger mentioned that every conversation with a patient is an opportunity to educate them on their potential allergies and treatment methods, especially at a time when concerns regarding the delta variant are prominent.